About US
LectomeBio is spearheading the revolution of cell-state-omics. We are building an ecosystem of integrated technologies that will shape how cell biologists in both industry and academia extract the truth behind cell biology, shape the future of cell biology, and shape the future of medicine and cell therapies for the benefit of knowledge and for patients. We are currently building our first products. These will be in a convenient flow cytometry based format coupled with access to our proprietary cell state analysis software. We will also be launching a high throughput platform for drug discovery and drug validation and suite of further products aimed at cell therapies. AI analysis will also be incorporated into our product suite.
We are currently in stealth mode – watch this space and follow our LinkedIn page for updates as we approach our launch phase.
We welcome contact from interested parties in exploring our exciting technology platforms further.
Intellectual Property
We have built a suite of intellectual property assets and an integrated product ecosystem to support our platform technologies.
Our central technology platform is supported by four patents, focusing on the cell biology behind our innovations and the use of sophisticated and software analysis. We are also developing further technologies to contribute to innovative ecosystem and portfolio of products.
We are supported by The University of Aberdeen in Scotland and Loughborough University in the Midlands of the UK, where the originating IP was developed.
Technology & Products
LectomeBio’s technology enables the determination of cell state. Cell states such as the healthy state vs the diseased state, cancerous state, aging state, as well as a multitude of other states that are central to cell biology. Our platform technologies can be used in ‘exploratory mode’ – by which we mean that the technology can be used with whatever the focus of your cell biology/biopharma needs, or alternatively in ‘defined mode’ – effectively through a targeted and guided approach to many of the cell biologists key and common areas of focus.
We are developing the technology in several formats; a high throughput drug discovery platform, a range of exploratory and defined kits, and platform formats for helping cell therapeutic companies (Stem Cell & CAR-T) to optimise yield and efficacy.
Our philosophy
Our guiding philosophy is to bring change to the Life Science Ecosystem for the benefit of science and for the benefit of medicine and therapy. This is central to the three founders’ vision. We know we have a game changing technology that will shape the future of the life sciences. We are aiming at maximising the benefit of this change not just for the company and investors, but importantly for the end users and ultimately for the recipients of better therapies. That is why our focus is to maximise the outlook of change through an ecosystem of integrated cell state technologies and an integrated ecosystem of customers and end-users of our technologies.
The team
Dr Paul Burrows, CEO
Founder & Inventor. Paul holds a PhD in biochemistry/cell biology from Imperial College London, and an MBA from Imperial College London.
Dr Patrick Cao, CsO
Founder & Inventor. Patrick holds a degree in natural Sciences from Cambridge University and a PhD from Cambridge University
Dr Dimitris Tampakis, CTo
Founder & Inventor. Dimitris holds a degree from The Democritus University of Thrace, an MSc from Aberdeen University, and a PhD from Loughborough University.
LectomeBio is also joined by Professor Nick Forsythe as the Board representative from Aberdeen University, and Dr Nick Gostick, the Board representative from Loughborough University. We are also joined by an expanding team of advisors including the eminent clinician Professor Mark Vickers and eminent immunologist Professor John Forrester.